Plain-English translation of NCT04342429 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is the first study to carefully examine intensity-modulated proton therapy (IMPT) as a treatment for small cell lung cancer. The treatment uses a focused beam of protons to target cancer cells while potentially sparing nearby healthy tissues. Researchers want to understand how often heart, lung, and esophageal side effects occur and compare them to what happens with traditional radiation therapy.
Small cell lung cancer grows quickly and radiation is an important part of treatment, but traditional radiation can sometimes damage the heart and other organs. This trial exists to see whether the new proton therapy approach can be gentler on these critical structures while still fighting the cancer effectively.
You likely qualify if…
You likely don't qualify if…
You would receive proton beam radiation therapy over several weeks (typically 15 to 33 treatments), delivered at 2 Gray per session. During your treatment course, your medical team would use imaging scans to check how your tumor is responding and adjust your treatment plan as needed. The study tracks side effects over time, particularly looking for heart problems, lung inflammation, and esophageal irritation.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States
Sponsor
Emory University
Enrollment target
~30 participants
Started
March 2020
Primary completion
May 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kristin Higgins, MD
Emory University-Winship Cancer Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.